DSM Biologics and Crucell Announce PER.C6 Licensing Deal With Sartorius Biotech GmbH
08 Jun 2007 -
Royal DSM N.V. and Crucell N.V. announced a non-exclusive PER.C6® research licensing deal with Goettingen, Germany-based Sartorius Biotech GmbH. Sartorius will use Crucell's key technology to evaluate monoclonal antibodies produced using PER.C6® cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant monoclonal antibodies. Crucell and Sartorius
further agreed to expand their PER.C6® collaboration by sharing technology and data on antibody production. Financial details were not disclosed.
Top
Contact
Print version
PDF version
Send article
RSS-Feed
